Cargando…
Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity. This phase IV trial aims to evaluate the lot-to-lot consistency, immunogenicity, and safety on a commercial scale in healthy adults, which could...
Autores principales: | Zhu, Dandan, Hu, Yuansheng, Jiang, Zhiwei, Yang, Tuantuan, Chu, Kai, Zhang, Hengming, Hu, Jialei, Meng, Xing, Tan, Zhijun, Wu, Jingliang, Lian, Xiaojuan, Li, Changgui, Pan, Hongxing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746504/ https://www.ncbi.nlm.nih.gov/pubmed/36441137 http://dx.doi.org/10.1080/21645515.2022.2135929 |
Ejemplares similares
-
Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022) -
Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
por: Wang, Yingdan, et al.
Publicado: (2022) -
CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022) -
Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
por: Bayhan, Gulsum Iclal, et al.
Publicado: (2022) -
Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
por: Cao, Cheng, et al.
Publicado: (2023)